Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Closes $26M Sentigen Acquisition

NEW YORK (GenomeWeb News) — Invitrogen today said it has closed its acquisition of Sentigen Holding.
 
The $25.9 million cash deal was announced in September.
 
Invitrogen paid $3.37 per share for the Phillipsburg, NJ-based company, which will become part of Invitrogen’s Discovery Sciences division, located in Madison, Wis.
 
With the acquisition, Invitrogen picks up Sentigen’s Tango assay system for protein interaction and GPCR screening and its assay ready cells that pare down the assay process, the company said.
 
At close of the business day Dec. 1, Sentigen had $11 million in cash on hand and cash investments, the company said. At mid-day today Sentigen shares were trading at $3.40.
The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.